Geron Corporation (GERN)
- Previous Close
3.7300 - Open
3.7100 - Bid 3.5800 x 200
- Ask 3.6100 x 700
- Day's Range
3.5500 - 3.8400 - 52 Week Range
1.6400 - 4.0500 - Volume
4,949,332 - Avg. Volume
12,725,908 - Market Cap (intraday)
2.109B - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3200 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.08
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
www.geron.comRecent News: GERN
Performance Overview: GERN
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GERN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GERN
Valuation Measures
Market Cap
2.20B
Enterprise Value
1.95B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.98k
Price/Book (mrq)
8.86
Enterprise Value/Revenue
8.22k
Enterprise Value/EBITDA
-11.15
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-41.47%
Return on Equity (ttm)
-112.29%
Revenue (ttm)
237k
Net Income Avi to Common (ttm)
-184.13M
Diluted EPS (ttm)
-0.3200
Balance Sheet and Cash Flow
Total Cash (mrq)
333.7M
Total Debt/Equity (mrq)
34.64%
Levered Free Cash Flow (ttm)
-100.51M
Research Analysis: GERN
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell